pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,064 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32globenewswire health20fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: TrumpRx adds generic drugs
    A deal with Mark Cuban, Amazon Pharmacy, and GoodRx is boosting TrumpRx's offerings.
    STAT · 2mo ago↗ source
  • BioMarin drug acquired in buyout misses goal in rare disease study
    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
    BioPharma Dive · 2mo ago↗ source
  • A migraine drugmaker heads to the public markets through reverse merger
    Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
    BioPharma Dive · 2mo ago↗ source
← prev
page 29 of 43
next →
20
fda medwatch20
fda recalls16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Dexcom CEO hints at future uses for CGM
    In this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.
    STAT · 2mo ago↗ source
  • STAT+: A new ranking of pharma companies by R&D performance
    Maryland drug board to cap price of Ozempic, TrumpRx partners with Cuban, GoodRx, and more biotech news
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
    The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
    STAT · 2mo ago↗ source
  • Relay drug shows early promise against rare blood vessel diseases
    While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
    A new set of lists ranks drug company laboratories on two criteria: innovation and invention.
    STAT · 2mo ago↗ source
  • The latest on Ebola: A travel ban and an old vaccine
    Affordable Care Act changes, drinking while pregnant, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: 1 in 8 women drink during pregnancy. Experts dread the consequences
    More than 1 in 8 pregnant women report drinking. Doctors warn fetal alcohol disorders may be more common than many realize, perhaps more common than autism.
    STAT · 2mo ago↗ source
  • Opinion: Britain embraces a Massachusetts experiment on tobacco regulation — just as the state might roll it back
    Britain embraces a Massachusetts experiment on tobacco regulation — just as the commonwealth might roll it back.
    STAT · 2mo ago↗ source
  • Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive
    “On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.
    STAT · 2mo ago↗ source
  • STAT+: Maryland state affordability board places a price cap on Ozempic
    Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the price of Ozempic.
    STAT · 2mo ago↗ source
  • STAT+: White House taps Amazon, GoodRx, and Mark Cuban to bolster TrumpRx
    Trump's drug discount platform adds 600 generic medications via major online pharmacies.
    STAT · 2mo ago↗ source
  • With no approved vaccine for Ebola outbreak, experts weigh testing a long shot
    With no approved vaccine for the fast-growing Ebola outbreak in the DRC, experts weigh testing one with unknown protection.
    STAT · 2mo ago↗ source
  • STAT+: Trump’s CMS to allow skimpier plans on ACA exchanges
    The new plans could leave patients on the hook for more of their health care costs.
    STAT · 2mo ago↗ source
  • STAT+: Why the WakeMed – Atrium Health hospital merger matters
    Hospital execs worked in secret on the deal for two years.
    STAT · 2mo ago↗ source
  • STAT+: AstraZeneca picks up FDA approval for hypertension drug
    The China question, FDA leadership shakeups, and other biotech news from The Readout
    STAT · 2mo ago↗ source
  • U.S. bans entry from Ebola-affected countries as American patient is identified
    In response to an Ebola outbreak, the U.S. has banned entry for noncitizens who have been in the Democratic Republic of the Congo, Uganda, or South Sudan recently.
    STAT · 2mo ago↗ source
  • FDA approves AstraZeneca’s new kind of hypertension drug
    Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
    BioPharma Dive · 2mo ago↗ source
  • Merck ADC, licensed from China, hits mark in first big global trial
    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
    BioPharma Dive · 2mo ago↗ source
  • Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
    The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
    The rejection may make the pharma firms remaining lawsuits more difficult.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
    The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart, pitting peers and partners against one another
    STAT · 2mo ago↗ source
  • Regeneron immunotherapy combo comes up short in melanoma trial
    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
    BioPharma Dive · 2mo ago↗ source